Posted by Michael Wonder on 20 Dec 2016
Pfizer receives approval in the European Union for Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine) in infants six weeks of age and older
19 December 2016 - Pfizer announced today the European Commission has approved an expanded indication for Nimenrix (meningococcal group A, C, W-135 and Y conjugate vaccine) for active immunisation against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.
Nimenrix is now the first and only MenACWY conjugate vaccine in the European Union that can be administered from six weeks of age with no upper age limit.
